Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Mallinckrodt Plc (MNK)

Mallinckrodt Plc (MNK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research PR Newswire - Mon Jul 13, 6:30AM CDT

DUBLIN , July 13, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript about the use of Acthar Gel (repository corticotropin injection) to treat certain severe...

MNK : 0.3402 (-14.97%)
Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis PR Newswire - Wed Jul 8, 6:00AM CDT

DUBLIN , July 8, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX ® (collagenase clostridium histolyticum) for the treatment...

MNK : 0.3402 (-14.97%)
Keenova Champions Men's Health Month with Education and Outreach PR Newswire - Mon Jun 1, 3:15PM CDT

Reddit AMA and New Sexual Health Screening Tool Headline the Awareness Month

MNK : 0.3402 (-14.97%)
Keenova Announces Newly Updated Peyronie's Disease Study Results at American Urology Association Meeting PR Newswire - Fri May 15, 6:36AM CDT

DUBLIN , May 15, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that new and final updated data from its dedicated ventral curvature analysis of Peyronie's disease and XIAFLEX ®...

MNK : 0.3402 (-14.97%)
Keenova Reports First Quarter 2026 Financial Results PR Newswire - Tue May 12, 5:30AM CDT

Strong First-Quarter Performance Driven by Acthar ® Gel 1  and XIAFLEX ® 2

MNK : 0.3402 (-14.97%)
Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking PR Newswire - Mon May 4, 6:30AM CDT

Dupuytren's contracture, a.k.a. Viking Hand, is a progressive hand condition affecting an estimated 13 million Americans

MNK : 0.3402 (-14.97%)
Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at Digestive Disease Week PR Newswire - Fri May 1, 6:30AM CDT

DUBLIN , May 1, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ ® (terlipressin) will...

MNK : 0.3402 (-14.97%)
Keenova Therapeutics to Report First Quarter 2026 Financial Results on May 12, 2026 PR Newswire - Thu Apr 30, 6:00AM CDT

DUBLIN , April 30, 2026 /PRNewswire/ --  Keenova Therapeutics plc , a leading developer and manufacturer of branded therapeutics, announced today that it will report its first quarter 2026 financial...

MNK : 0.3402 (-14.97%)
Keenova Announces Unaudited Fourth Quarter 2025 Financial Results PR Newswire - Tue Mar 31, 5:30AM CDT

Robust Fourth-Quarter Performance Driven by Strength in Acthar ® Gel 1  and XIAFLEX ® 2

MNK : 0.3402 (-14.97%)
Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at the SHM Converge PR Newswire - Fri Mar 27, 6:30AM CDT

DUBLIN , March 27, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ ® (terlipressin)...

MNK : 0.3402 (-14.97%)

Barchart Exclusives

FuelCell Just Landed the Deal That Could Finally Turn It Profitable Barchart - 31 minutes ago
FuelCell's new Siemens partnership targets commercial projects of 100 MW and up, the exact threshold management says it needs to turn its EBITDA positive. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.